Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

4Total
P 3 (4)

Trial Status

Recruiting3
Active Not Recruiting3

Clinical Trials (6)

Showing 6 of 6 trials
NCT02567435Phase 3Active Not Recruiting

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

NCT04994132Phase 3Active Not Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

NCT05304585Phase 3RecruitingPrimary

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

NCT03296371Active Not Recruiting

Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma

NCT03382158Recruiting

International PPB/DICER1 Registry

NCT06669013Phase 3Recruiting

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

Showing all 6 trials

Research Network

Activity Timeline